

---

Subject	<b>Programme and Policy Committee Chair Report</b>
---------	----------------------------------------------------

---

Category	<b>For Information</b>
----------	------------------------

---

### **Section A: Introduction**

- This report provides the Board with an overview of the activities of the Programme and Policy Committee (PPC) since the Committee Chair last reported to the Board in December 2023.
- On 15-16 May 2024, the PPC held an in-person meeting. During the meeting, the Committee discussed a number of important topics for the Alliance and agreed on recommendations which are being put forward to the Board at its 6-7 June 2024 meeting for consideration.
- The PPC Chair report is attached in the form of a presentation as Annex A, the PPC recommendations to the Board are attached as Annex B, and a set of overview slides on Gavi's Eligibility, Transition and Co-Financing (ELTRACO) model that were used by the PPC in its last meeting are attached as Annex C.

### **Annexes**

**Annex A:** PPC Chair report

**Annex B:** PPC recommendations to Gavi Alliance Board

**Annex C:** Overview slides on ELTRACO model

# PROGRAMME AND POLICY COMMITTEE CHAIR REPORT

BOARD MEETING

**Anne Schuchat**

6-7 June 2024, Geneva, Switzerland

# PPC Meeting, 15-16 May 2024

## Discussion, Guidance and Information Items

- CEO Update
- Read out from the Audit and Finance Committee (*Information item with no discussion*)
- Gavi 5.1 Strategy, Programmes and Partnerships: Progress, Risks and Challenges
- Gavi 6.0: Update on Design and Operationalisation
  - Part A: Future of Gavi's Eligibility, Co-Financing and Transition Model and Middle-Income Countries Approach
  - Part B: Health Systems Strategy
  - Part C: Climate Change Approach (*Taken as read, PPC invited to share comments in writing*)
- Joint Alliance Update on Country Programmes (*Taken as read with no discussion due to time constraints*)

# PPC Meeting, 15-16 May 2024

## Discussion, Guidance and Information Items (continued)

- Report of the Independent Review Committee (IRC)
- Update on Collaboration with Other Organisations
- Update on EVOLVE project

# PPC Meeting, 15-16 May 2024

## Recommendations to the Board

- Vaccine Investment Strategy 2024 – Investment Cases (*Board Agenda Item 10*)
- Day Zero Financing Facility for Pandemics: First Response Fund (*Board Agenda Item 11*)
- African Vaccine Manufacturing Accelerator (AVMA) (*Board Agenda Item 11*)

# PPC Meeting, 15-16 May 2024

## CEO Update

- The Committee extended a warm welcome to Sania Nishtar as the new Gavi CEO, and expressed deep appreciation of her commitment to place countries at the top of her priorities and advance the Lusaka Agenda
- With respect to resource mobilisation and the constrained fiscal space in countries, PPC members underlined the need for maximising available resources through focused approaches and joint efforts
- Emphasised the importance of strengthening partnerships and advancing the collaboration agenda, while remaining cognisant of what Gavi can and cannot do
- Highlighted the zero-dose agenda, noting that a standard approach will not address this issue, and with fragility being a critical determinant

# PPC Meeting, 15-16 May 2024

## Gavi 5.1 Strategy, Programmes and Partnerships: Progress, Risks and Challenges

- Provided detailed comments related to Strategic Goal 1 including on outbreaks, cholera, malaria and human papillomavirus vaccine (HPV) revitalisation
- Advised on Big Catch-Up operationalisation, co-financing, and vaccine market health
- With respect to malaria, emphasised the need to address inaccurate rumours about vaccine effectiveness and to build on lessons learned to date
- On HPV, flagged the opportunity to switch to an off-label, single dose regimen following recent recommendations from the WHO Strategic Group of Experts on Immunisation (SAGE)
- Noted for co-financing that it will be important to monitor the actual source of funds used to pay Gavi co-financing

# PPC Meeting, 15-16 May 2024

## Gavi 6.0: Update on Design and Operationalisation

- Welcomed the consultative approach in designing the Gavi 6.0 strategy and confirmed its support of the overall design of Gavi 6.0 as well as proposed approach to operationalise it
- Welcomed the emerging 6.0 priorities and associated impact
- Emphasised the importance of reflecting country priorities and recommendations from the Togo workshop in early 2024, noting some misalignment between these priorities and the April 2024 Board retreat outcomes
- In relation to the preliminary funding estimates, encouraged the Secretariat to be ambitious in asking for a budget to meet the Gavi 6.0 agenda and expressed concern on scale back on health systems funding discussed at the Board retreat
- In relation to collaboration with new partners, stressed the importance of building on existing partnerships and engaging with non-governmental actors particularly in fragile settings, and the importance of the Lusaka Agenda



# PPC Meeting, 15-16 May 2024

## Future of Gavi's Eligibility, Transition and Co-Financing (ELTRACO) Model and Middle-Income Countries Approach

- Broadly supported the 'direction of travel' for this workstream proposed for Gavi 6.0 – with detailed design choices to be further explored as part of the Funding Policy Review (FPR)
- Emphasised that the proposed enhanced ELTRACO model could have consequential implications for Gavi 6.0, specifically on health impact, equity, sustainability and market shaping
- Indicated that the FPR should pressure test the model's ability to address the affordability challenges of countries in Gavi 6.0 and put a particular focus on the future eligibility indicators and threshold while also being cognisant of Gavi's ability to finance the model

# PPC Meeting, 15-16 May 2024

## Future of Gavi's ELTRACO Model and Middle-Income Countries Approach (continued)

On the proposed evolution of the MICs approach - the new 'Catalytic phase':

- On Objective 1 (Drive sustainable introduction of key missing vaccines), there was emerging consensus that former and never Gavi countries should be eligible (needs-based) if International Development Association (IDA)-eligible and/or Low- and Middle-Income Country (LMIC). Further work is needed via FPR on access to sustainable vaccine prices for MICs
- On Objective 2 (Prevent and mitigate backsliding), there was emerging consensus that both former Gavi and Never Gavi MICs should be eligible (needs-based) if IDA-eligible and/or LMIC to access global and regional 'public goods,' eg global TA platforms, regional peer learning, MFF. Only selected former Gavi MICs should be eligible (needs-based) for Targeted Interventions at country level
- On Objective 3 (Ensure support for fragile countries), there was emerging consensus that former Gavi MICs should be eligible (needs-based) if IDA-eligible and/or LMIC; however, there was no consensus on never Gavi countries. Further exploration is needed through FPR of fragility support for never Gavi countries; and feasibility of support within US\$ 250 million envelope

# PPC Meeting, 15-16 May 2024

## Health Systems Strategy

- Expressed enthusiasm for the vision of innovation presented by CEO, and were broadly supportive of the objectives of a Health Systems Strategy and shifts described in the paper, with an ask to develop a comprehensive theory of change
- In relation to differentiation, broadly supported the approach and asked that the Secretariat explore designing this in a way that incentivises domestic investment in routine immunisation
- Supported consolidation of funding levers and a holistic approach, and expressed interest in an analysis of an allocation formula approach. There was also a request to think about how to join up planning and incentives for campaigns as part of the HS Strategy
- Advised not to impose new indicators on countries only to serve Gavi measurement needs, but to be more deliberate in identifying what metrics are critical for countries to collect.
- Expressed strong concerns on the implications of a cut in HSS funding both in regards to existing programmes and the zero-dose agenda.

# PPC Meeting, 15-16 May 2024

## Report of the Independent Review Committee (IRC)

- Welcomed the update by Dr Rose Leke, IRC Chair, with Bolanle Oyeledun and Pierre Corneille Namaharo, IRC Vice Chairs, and highlighted the importance of the IRC's work
- Emphasised the importance of collaboration with the Global Fund to Fight AIDS, Tuberculosis and Malaria, particularly on possible joint review processes and using the same applications that include joint indicators and monitoring processes, particularly for the malaria applications. Noted as well that more work is needed to advance this planning
- Commended gender-related considerations in the IRC analysis and enquired about gaps
- Underlined the need to continue focusing on strengthening routine immunisation (RI), building on innovative approaches and making the best use of available funds
- Expressed interest in hearing IRC reflections on the in-country IRC reviews of funding requests, given their link to ownership and country engagement
- Appreciated the positive examples of best practices highlighted in the report to the PPC and asked that these findings be disseminated broadly to support countries learning from each other

# PPC Meeting, 15-16 May 2024

## Update on Collaboration with Other Organisations

- Welcomed the ambitious collaboration agenda and urged Gavi to move towards joint efforts with key partner organisations, underlining transparency, simplification and strategic partnerships for impact
- Expressed appreciation for the collaborative tone on the malaria workstreams, including the joint Gavi-Global Fund Board technical briefing on malaria in April 2024
- Enquired about the Terms of Reference of the potential joint Committee Working Group and called on the Secretariat to avoid creating parallel decision-making bodies
- Welcomed the strengthened partnership with Africa CDC, given the importance of aligning activities across the Alliance with the broader partnership landscape and leveraging the capabilities of each partner
- Underlined the importance of the Lusaka Agenda to ensure putting countries at the forefront

# PPC Meeting, 15-16 May 2024

## Update on EVOLVE project

- Expressed continued strong support for the EVOLVE agenda and also supported the proposed strategic shifts in the target operating model
- Encouraged the Secretariat in its shift from donor-centric grant management to country-centric, in line with the Lusaka Agenda
- Recognised that the model's anticipated greater efficiency and effectiveness would outweigh the required trade-offs and potential change in risk-appetite
- Supported the proposal to consolidate seven different cash grants into one cash envelope for Gavi 6.0, but expressed differing views of whether Partners' Engagement Framework (PEF) Targeted Country Assistance should also be consolidated with those cash grants.

# PPC Meeting, 15-16 May 2024

## Recommendations to the Board

- Listed in Annex B
- Further details from the PPC discussions contained in the relevant papers to the Board (indicated on slide 4)

# Thank you



# REVIEW OF DECISIONS

PROGRAMME AND POLICY COMMITTEE  
15-16 May 2024, Prangins, Switzerland

# Decision 1: Vaccine Investment Strategy 2024 – Investment Cases (1/4)

The Gavi Alliance Programme and Policy Committee (PPC) recognised that this Vaccine Investment Strategy (VIS) is taking place in a different global health and fiscal landscape with significant pressures on health systems, vaccination schedules and changing epidemiology due to climate change and urbanisation.

As the menu of vaccines available across the lifecourse increases, countries may require technical support to strengthen decision-making capacities on vaccine prioritisation and optimisation and support to strengthen their health systems to deliver them.

The PPC also recognised the importance of the VIS for long-term market signalling to manufacturers despite the many unknowns.

# Decision 1: Vaccine Investment Strategy 2024 – Investment Cases (2/4)

Annex B

Considering this, the Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board, subject to the availability of funding for the 2026-2030 period following Gavi's replenishment for that period, that it:

- a) **Approve** in principle, support for a **tuberculosis (TB) vaccine programme**, contingent on the availability of a licensed product for adults/adolescents, outcomes of regulatory and technical review processes (including WHO prequalification and SAGE recommendation), and meeting the financial assumptions used as the basis for the TB investment case set out in Annex B to Doc 09;
- b) **Approve** in principle, support for a **dengue vaccine programme**, contingent on outcomes of regulatory and technical review processes and the availability and application of disease burden data in Gavi supported countries to inform the design of a vaccine programme, and meeting the financial assumptions used as the basis for the dengue investment case set out in Annex B to Doc 09;
- c) **Approve** in principle, support for a **group B streptococcus (GBS) vaccine programme**, contingent on the availability of a licensed product, outcomes of regulatory and technical review processes (including WHO prequalification and SAGE recommendation), and meeting the financial assumptions used as the basis for the GBS investment case set out in Annex B to Doc 09;
- d) **Note** continued exploration by the Secretariat of the need for, and design of, timely **market shaping interventions** aimed at ensuring that **TB vaccine supply** matches anticipated demand with minimal lag;

# Decision 1: Vaccine Investment Strategy 2024 – Investment Cases (3/4)

- e) **Note** the expected public health impact of a future **shigella** vaccine programme in Gavi-supported countries and that continued vaccine development is important, and **request** the Secretariat to revert to the PPC with an updated investment case for a shigella vaccine programme when there is further information on country product preferences and timelines for technical guidance, policy and regulatory review processes;
- f) **Approve** the VIS learning agendas for 2026-2030 for **shigella, GBS, dengue and tuberculosis** as described in Annex B to Doc 09;
- g) **Approve** in principle, support for a **global stockpile of hepatitis E vaccines**, contingent on outcomes of regulatory and technical review processes (WHO prequalification), and meeting the financial assumptions used as the basis for the hepatitis E investment case set out in Annex B to Doc 09;
- h) **Approve** in principle, support for a **global stockpile of mpox vaccines**, contingent on outcomes of regulatory and technical review processes, and meeting the financial assumptions used as the basis for the mpox investment case set out in Annex B to Doc 09;
- i) **Note** the financial implications associated with the above approvals (taken as a whole) for **2026-2030** are expected to be approximately US\$ 56.7 million, comprised of approximately US\$ 32.9 million for vaccine and operational cost support and approximately US\$ 23.8 million for learning agenda and reporting activities;
- j) **Note** that the **routine COVID-19 programme will be discontinued** following the completion of the current 2024-2025 programme, and that support for COVID-19 in the event of a worst-case scenario would be considered through Gavi's pandemic preparedness, prevention and response activities;

# Decision 1: Vaccine Investment Strategy 2024 – Investment Cases (4/4)

- k) **Approve** the VIS learning agendas starting from **2024** for **hepatitis E** and **mpox** vaccines, as described in Annex B to Doc 09 and **note** that the financial implications associated with the above approvals for **2024-2025** are expected to be approximately US\$ 0.5 million, which the Secretariat will seek to absorb from the Board-approved budget for the 2021-2025 Strategic Period; and
- l) **Approve** from 2024, a role for the Gavi Alliance in responding to the ongoing mpox outbreak, including coordinating mpox dose donations in response to the ongoing outbreak in the Democratic Republic of the Congo and further potential outbreaks in surrounding countries. Building on lessons learnt from the COVAX Facility, this coordination role will be contingent upon favorable conditions, including the availability of resources, clear demand from countries, regulatory compliance, and reaching agreements that are actionable by all parties involved.

# Decision 2: Day Zero Financing Facility for Pandemics: First Response Fund

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

**Approve** the specifications of the programmatic design of the First Response Fund of the Day Zero Financing Facility for Pandemics, including the Fund's programmatic parameters and eligibility criteria, as set out in Annex A to Doc 11.

# Decision 3: African Vaccine Manufacturing Accelerator (AVMA)

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** the amendments to the key terms of the African Vaccine Manufacturing Accelerator (AVMA) as set out in Annex A to Doc 12;
- b) **Note** the AVMA Monitoring, Evaluation & Learning (MEL) Framework, including proposals for periodic course correction as set out in Annex B to Doc 12; and
- c) **Note** the Key dependencies as set out in Annex C to Doc 12.

# Thank you



# OVERVIEW SLIDES ON ENHANCED ELTRACO MODEL (AS OF 16 MAY 2024)

# Overview of proposed shifts for the enhanced ELTRACO model (as of 16 May 2024)

Annex C

Proposed shifts	Work in progress	Big open questions to be further explored in the Funding Policy Review (FPR) in second half of 2024
<b>a</b> Introducing price sensitivity in Initial Self Financing (ISF) countries	Yes	<ul style="list-style-type: none"> <li>n/a</li> </ul>
<b>b</b> Updating Gavi's eligibility threshold	<p>2'500 GNI p.c., and reintroduce Gavi vaccine financing support for previously self-financed programmes for countries regaining eligibility or re-entering preparatory transition</p> <p>Acknowledge model to be revisited for Gavi 7.0</p>	<ul style="list-style-type: none"> <li>Confirm whether to <b>maintain GNI p.c. as the sole eligibility indicator</b> or to <b>supplement it by another indicator (under shift e)</b></li> <li>Concretise specifics of Gavi vaccine financing support for previously <b>fully-self-financed</b> vaccine programmes</li> </ul>
<b>c</b> Slowing down co-financing increase in Preparatory Transition (PT)	Yes	<ul style="list-style-type: none"> <li>n/a</li> </ul>
<b>d</b> Providing minimum support for new vaccine introductions in Accelerated Transition (AT)	Yes	<ul style="list-style-type: none"> <li>Concretise the <b>number of years and vaccine programmes</b> for which additional support should be granted</li> </ul>
<b>e</b> Decoupling the transition from vaccine and cash support	Yes	<ul style="list-style-type: none"> <li>Define the <b>programmatic indicators</b> for decoupling</li> </ul>
<b>f</b> Differentiating co-financing rules for a subset of fragile countries facing humanitarian crisis	Yes	<ul style="list-style-type: none"> <li>Define eligibility criteria for fragile countries to <b>multi-year waiver</b> and/or <b>gradual co-financing ramp-up</b></li> </ul>

# Overview of the Catalytic phase (as of 16 May 2024) Annex C

	Work in progress	Big open questions to be further explored in the Funding Policy Review (FPR) in second half of 2024
Objective 1: Drive sustainable introduction of key missing vaccines	<ul style="list-style-type: none"> <li>Former &amp; Never Gavi countries are eligible (needs-based) if IDA eligible and/or LMIC</li> </ul>	<ul style="list-style-type: none"> <li>Further explore access to sustainable vaccine prices for MICs (e.g. MICs Financing Facility (MFF))</li> </ul>
Objective 2: Prevent and mitigate backsliding	<ul style="list-style-type: none"> <li>Former Gavi MICs eligible (needs-based) if IDA eligible and/or LMIC</li> <li>Never Gavi MICs have access to “public goods,” e.g. global TA platforms, regional peer learning, MFF</li> </ul>	<ul style="list-style-type: none"> <li>n/a</li> </ul>
Objective 3: Ensure support for fragile countries	<ul style="list-style-type: none"> <li>Former Gavi MICs eligible (needs-based) if IDA eligible and/or LMIC</li> <li>No consensus on never Gavi</li> </ul>	<ul style="list-style-type: none"> <li>Explore fragility support for never Gavi countries</li> <li>Feasibility of support within US\$ 250 million envelope to be explored</li> </ul>
Total envelope	<ul style="list-style-type: none"> <li>US\$ 250 million</li> </ul>	